CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today

(NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will host a conference call and live audio webcast on Thursday, August 6, 2015 at 9:00 a.m. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously, affect virus growth rate and pathogenicitiy Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Could a contraceptive app be as good as the pill? Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing. Genocea hsv vaccine Genocea Biosciences has developed GEN-003, a first-in-class protein subunit T cell-enabled therapeutic vaccine, . . Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Genocea’s ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; that current results may not be predictive of future results; that even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Genocea’s ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; Genocea’s ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; the availability of qualified personnel and other factors set forth under “Risk Factors” in Genocea’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other filings with the Securities Exchange Commission (the “SEC”).

General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2016 were $3.9 million, compared to $3.4 million for the same period in 2015. A seventh group received placebo. However, it frequently develops a clinically significant disease in immuno-compromised patients, and has also recently been implicated in a number of population-wide chronic conditions including atherosclerosis, type 1 diabetes, inflammatory bowel diseases, lupus and even cancer. joined the company as senior vice president of pharmaceutical sciences. While Cambrex sports a Zacks Rank #1 (Strong Buy), Arena and Anika carry a Zacks Rank #2 (Buy). For more information about this clinical study of GEN-003 please visit www.clinicaltrials.gov. 10 solid month outbreak free!!!

ASP0113 was initially developed by Vical and is now in partnership with Astellas for further development and commercialization. Vical currently carries a Zacks Rank #3 (Hold). Shares traded for $1.30 on July 29, 2014, dropped to $1.00 on Jan. No differences in treatment-emergent adverse events were observed between the two treatments. are caused by HSV type 2, which GEN-003 is targeting. Conference Call Genocea management will host a conference call and webcast today at 9 a.m. Ph.D., will present the findings.

According to the company’s press release, more than 400 million people across the world are affected by genital herpes. Pritelivir has also demonstrated its efficacy when compared with the standard treatment of valacyclovir for genital HSV-2 infection in a Phase II clinical trial. “The patient response and rapid enrollment we experienced underscore the unmet medical need for new treatment options with novel mechanisms of action for this lifelong disease,” Hetherington said. – Trial meets statistical significance vs. GEN-003 includes the antigens ICP4 and gD2 along with Matrix-M2TM adjuvant, which Genocea licenses from Novavax, Inc. The genital lesion rate is an important overall measure of disease that captures both the frequency and duration of recurrences, both of which are important to both patients and their caregivers. Both the monovalent and bivalent vaccines were generally well tolerated, Vical said, adding that no grade 4 adverse events or serious adverse events related to vaccination had been observed.

Today, Genocea highlighted the significant body of clinical data it has generated over the course of three clinical trials for what may be the first new therapy for genital herpes in more than 20 years. As a compound derived from a novel chemical class (thiazolylamides), pritelivir is active against both types of herpes simplex virus (HSV-1 and HSV-2) causing labial and genital herpes, respectively, and retains activity against viruses which have become resistant to marketed drugs. HSV-2 infections are persistent and can result in debilitating genital lesions, as well as periodic virus shedding placing sexual partners at risk. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. According to top-line data from the study, which compared the pre-vaccination measurements for each cohort to the measurements taken during the swabbing period in months 2 and 3 following the last vaccine dose, both the monovalent and bivalent vaccines failed to meet the primary endpoint.